(MedPage Today) — BARCELONA — A small-molecule oral drug shaping up as a first-in-class to treat various forms of lupus performed well in a phase II trial, despite — or perhaps even because of — missing its primary endpoint, a presentation…
Source link : https://www.medpagetoday.com/meetingcoverage/eular/116080
Author :
Publish date : 2025-06-14 20:00:00
Copyright for syndicated content belongs to the linked Source.
